In vitro effect of pachymic acid on the activity of Cytochrome P450 enzymes

References

• Ahmad N, Mukhtar H. (2004). Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol 123:417–25.
   PubMed Web of Science ®Google Scholar
• Akihisa T, Nakamura Y, Tokuda H, et al. (2007). Triterpene acids from Poria cocos and their anti-tumor-promoting effects. J Nat Prod 70:948–53.
   PubMed Web of Science ®Google Scholar
• Basheer L, Kerem Z. (2015). Interactions between CYP3A4 and Dietary Polyphenols. Oxid Med Cell Longev 2015:854015.
   PubMed Web of Science ®Google Scholar
• Dong G, Zhou Y, Song X. (2018). In vitro inhibitory effects of bergenin on human liver cytochrome P450 enzymes. Pharm Biol 56:620–5.
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Zhang YY, Ge GB, Huo H, et al. (2010). Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 69:193–9.
   PubMed Web of Science ®Google Scholar
• Flora DR, Rettie AE, Brundage RC, Tracy TS. (2017). CYP2C9 genotype-dependent warfarin pharmacokinetics: impact of CYP2C9 Genotype on R- and S-Warfarin and their oxidative metabolites. J Clin Pharmacol 57:382–93.
   PubMed Web of Science ®Google Scholar
• Grimm SW, Einolf HJ, Hall SD, et al. (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355–70.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2017). Intersection of the roles of cytochrome P450 enzymes with xenobiotic and endogenous substrates: relevance to toxicity and drug interactions. Chem Res Toxicol 30:2–12.
   PubMed Web of Science ®Google Scholar
• Hao X, Yuan J, Xu Y, et al. (2018). In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes. Xenobiotica 48:1185–91.
   PubMed Web of Science ®Google Scholar
• Jeong JW, Lee WS, Go SI, et al. (2015). Pachymic acid induces apoptosis of EJ bladder cancer cells by DR5 Up-Regulation, ROS generation, modulation of Bcl-2 and IAP family members. Phytother Res 29:1516–24.
   PubMed Web of Science ®Google Scholar
• Kim TG, Lee YH, Lee NH, et al. (2013). The antioxidant property of pachymic acid improves bone disturbance against AH plus-induced inflammation in MC-3T3 E1 cells. J Endod 39:461–6.
   PubMed Web of Science ®Google Scholar
• Lang J, Li W, Zhao J, et al. (2017). Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes. Xenobiotica 47:849–55.
   PubMed Web of Science ®Google Scholar
• Lee YH, Lee NH, Bhattarai G, et al. (2013). Anti-inflammatory effect of pachymic acid promotes odontoblastic differentiation via HO-1 in dental pulp cells. Oral Dis 19:193–9.
   PubMed Web of Science ®Google Scholar
• Li J, Wen H, Gao Z. (2019). In vitro inhibitory effects of phellodendrine on human liver cytochrome P450 enzymes. Xenobiotica 50:154–9.
   Web of Science ®Google Scholar
• Liu L, Cao X, Li T, Li X. (2019). Effects of catalpol on the activity of human liver cytochrome P450 enzymes. Xenobiotica 49:1289–95.
   PubMed Web of Science ®Google Scholar
• Liu L, Sun S, Rui H, Li X. (2017). In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes. Pharm Biol 55:1868–74.
   PubMed Web of Science ®Google Scholar
• Lu C, Ma J, Cai D. (2017). Pachymic acid inhibits the tumorigenicity of gastric cancer cells by the mitochondrial pathway. Anticancer Drugs 28:170–9.
   PubMed Web of Science ®Google Scholar
• Motawi TK, Teleb ZA, El-Boghdady NA, Ibrahim SA. (2014). Effect of simvastatin and naringenin coadministration on rat liver DNA fragmentation and cytochrome P450 activity: an in vivo and in vitro study. J Physiol Biochem 70:225–37.
   PubMed Web of Science ®Google Scholar
• Perloff ES, Mason AK, Dehal SS, et al. (2009). Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 39:99–112.
   PubMed Web of Science ®Google Scholar
• Qi XY, Liang SC, Ge GB, et al. (2013). Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol 56:392–7.
   PubMed Web of Science ®Google Scholar
• Song J, Dai H, Zhang H, et al. (2019). Influence of glycyrrhetinic acid on the pharmacokinetics of warfarin in rats. Xenobiotica. doi: 10.1080/00498254.2019.1671637.
   Web of Science ®Google Scholar
• Srinivas NR. (2016). Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters. Gen Physiol Biophys 35:243–58.
   PubMed Web of Science ®Google Scholar
• Wang FY, Lv WS, Han L. (2015). Determination and pharmacokinetic study of pachymic acid by LC-MS/MS. Biol Pharm Bull 38:1337–44.
   PubMed Web of Science ®Google Scholar
• Xia MM, Wang L, Pa PP, et al. (2014). The role of CYP2C9 genetic polymorphisms in the oxidative metabolism of diclofenac in vitro. Pharmazie 69:898–903.
   PubMed Web of Science ®Google Scholar
• Yamaura K, Shimada M, Nakayama N, Ueno K. (2011). Protective effects of goldenseal (Hydrastis canadensis L.) on acetaminophen-induced hepatotoxicity through inhibition of CYP2E1 in rats. Pharmacognosy Res 3:250–5.
   PubMedGoogle Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Liu Y, Cheng J, et al. (2007). Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci 10:496–503.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Zhang Y, Li XY, et al. (2017). Antitumor activity of the pachymic acid in nasopharyngeal carcinoma cells. Ultrastruct Pathol 41:245–51.
   PubMed Web of Science ®Google Scholar